Sign in or create an account to add this stock to your watchlist.
About Intersect ENT (NASDAQ:XENT)
Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. The company is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XENT
CUSIPN/A
Phone650-641-2100
Debt
Debt-to-Equity RatioN/A
Current Ratio8.99
Quick Ratio8.39
Price-To-Earnings
Trailing P/E Ratio-70.18
Forward P/E Ratio-62.34
P/E GrowthN/A
Sales & Book Value
Annual Sales$96.30 million
Price / Sales12.49
Cash FlowN/A
Price / CashN/A
Book Value$3.93 per share
Price / Book10.15
Profitability
EPS (Most Recent Fiscal Year)($0.56)
Net Income$-16,360,000.00
Net Margins-15.73%
Return on Equity-13.67%
Return on Assets-12.06%
Miscellaneous
Employees327
Outstanding Shares30,140,000
Intersect ENT (NASDAQ:XENT) Frequently Asked Questions
What is Intersect ENT's stock symbol?
Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."
How were Intersect ENT's earnings last quarter?
Intersect ENT (NASDAQ:XENT) issued its quarterly earnings results on Tuesday, May, 1st. The medical equipment provider reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.02. The medical equipment provider earned $24.70 million during the quarter, compared to analysts' expectations of $23.66 million. Intersect ENT had a negative return on equity of 13.67% and a negative net margin of 15.73%. The business's quarterly revenue was up 20.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.23) earnings per share. View Intersect ENT's Earnings History.
When is Intersect ENT's next earnings date?
What price target have analysts set for XENT?
9 equities research analysts have issued twelve-month price objectives for Intersect ENT's shares. Their forecasts range from $31.00 to $48.00. On average, they expect Intersect ENT's share price to reach $37.5714 in the next year. View Analyst Ratings for Intersect ENT.
What are Wall Street analysts saying about Intersect ENT stock?
Here are some recent quotes from research analysts about Intersect ENT stock:
- 1. Canaccord Genuity analysts commented, "We reiterate our BUY rating on XENT and view ongoing share weakness as a buying opportunity. Specifically, shares are down ~9% intraday following the release of preliminary CMS guidelines that deny XENT’s request for a standalone J-code for Sinuva. The decision was disclosed in the CMS preliminary agenda for the upcoming Public Meeting for Drugs, Biological, and Radiopharmaceuticals held on May 15, 2018 (link). In the preliminary guideline CMS denies XENT’s request for a product-specific J-code and instead assigns Sinuva to an old and soon to be defunct (as of Jan 1, 2019) Category 3 CPT code – 0406T. Our conversation with management suggests the decision in the preliminary guidelines was likely an oversight on the part of CMS and something that will likely be addressed when the topic presented at the meeting on May 15." (5/7/2018)
- 2. According to Zacks Investment Research, "Intersect ENT, Inc. is a commercial drug-device company. The Company's initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California. " (5/5/2018)
- 3. Northland Securities analysts commented, "We are raising our FY18 and FY19 numbers, in part due to elevated expectations on SINUVA. In our view, this story of marginal beats and managing Street expectations" is not enough to elevate the stock from its current 10x sales multiple." (5/2/2018)
Who are some of Intersect ENT's key competitors?
Some companies that are related to Intersect ENT include Merit Medical Systems (MMSI), NovoCure (NVCR), NuVasive (NUVA), Nevro (NVRO), iRhythm (IRTC), Mazor Robotics (MZOR), Luminex (LMNX), Glaukos (GKOS), ATRION (ATRI), Orthofix (OFIX), MiMedx Group (MDXG), K2M Group (KTWO), CryoLife (CRY), OraSure Technologies (OSUR) and Cardiovascular Systems (CSII).
Who are Intersect ENT's key executives?
Intersect ENT's management team includes the folowing people:
- Ms. Lisa D. Earnhardt, Chief Exec. Officer, Pres and Director (Age 48)
- Ms. Jeryl L. Hilleman M.B.A, Chief Financial Officer (Age 60)
- Mr. Richard E. Kaufman, Chief Operating Officer (Age 56)
- Mr. David A. Lehman, Gen. Counsel & Sec. (Age 57)
- Ms. Gwen R. Carscadden, Chief People Officer (Age 57)
Has Intersect ENT been receiving favorable news coverage?
Media stories about XENT stock have trended somewhat positive on Friday, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Intersect ENT earned a coverage optimism score of 0.07 on Accern's scale. They also gave headlines about the medical equipment provider an impact score of 46.56 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Intersect ENT's major shareholders?
Intersect ENT's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.43%), Federated Investors Inc. PA (2.93%), Neuberger Berman Group LLC (1.77%), Rock Springs Capital Management LP (1.36%), Lord Abbett & CO. LLC (1.28%) and Northern Trust Corp (1.18%). Company insiders that own Intersect ENT stock include Amy Wolbeck, David Aaron Lehman, Frederic H Moll, Gwen R Carscadden, James Stambaugh, Jeryl L Hilleman, Lisa D Earnhardt and Richard E Kaufman. View Institutional Ownership Trends for Intersect ENT.
Which institutional investors are selling Intersect ENT stock?
XENT stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Neuberger Berman Group LLC, Citigroup Inc., Millennium Management LLC, BlackRock Inc., GSA Capital Partners LLP, Tiverton Asset Management LLC and A.R.T. Advisors LLC. Company insiders that have sold Intersect ENT company stock in the last year include David Aaron Lehman, Frederic H Moll, Gwen R Carscadden, Jeryl L Hilleman, Lisa D Earnhardt and Richard E Kaufman. View Insider Buying and Selling for Intersect ENT.
Which institutional investors are buying Intersect ENT stock?
XENT stock was acquired by a variety of institutional investors in the last quarter, including Matarin Capital Management LLC, Public Employees Retirement Association of Colorado, Loomis Sayles & Co. L P, Royal Bank of Canada, Bamco Inc. NY, Sivik Global Healthcare LLC, Rock Springs Capital Management LP and Thrivent Financial for Lutherans. View Insider Buying and Selling for Intersect ENT.
How do I buy shares of Intersect ENT?
Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intersect ENT's stock price today?
One share of XENT stock can currently be purchased for approximately $39.90.
How big of a company is Intersect ENT?
Intersect ENT has a market capitalization of $1.19 billion and generates $96.30 million in revenue each year. The medical equipment provider earns $-16,360,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Intersect ENT employs 327 workers across the globe.
How can I contact Intersect ENT?
Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected]
MarketBeat Community Rating for Intersect ENT (XENT)
MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote "Outperform" if you believe XENT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Intersect ENT (NASDAQ:XENT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
9 Wall Street analysts have issued ratings and price targets for Intersect ENT in the last 12 months. Their average twelve-month price target is $37.5714, suggesting that the stock has a possible downside of 5.84%. The high price target for XENT is $48.00 and the low price target for XENT is $31.00. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.78 | 2.82 | 2.80 | 2.78 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $37.5714 | $33.4286 | $33.4286 | $30.5714 |
| Price Target Upside: | 5.84% downside | 20.26% downside | 3.17% upside | 7.27% upside |
Intersect ENT (NASDAQ:XENT) Consensus Price Target History
Intersect ENT (NASDAQ:XENT) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
Intersect ENT (NASDAQ:XENT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Intersect ENT (NASDAQ XENT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.90%
Institutional Ownership Percentage: 88.95%
Intersect ENT (NASDAQ XENT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/3/2018 | Jeryl L Hilleman | CFO | Sell | 12,833 | $39.94 | $512,550.02 | 36,265 |  |
| 4/16/2018 | Lisa D Earnhardt | Insider | Sell | 15,000 | $39.59 | $593,850.00 | 499,683 | |
| 4/3/2018 | Jeryl L Hilleman | CFO | Sell | 12,833 | $37.66 | $483,290.78 | 36,265 | |
| 3/15/2018 | Lisa D Earnhardt | Insider | Sell | 15,000 | $38.32 | $574,800.00 | 499,683 | |
| 3/6/2018 | Jeryl L Hilleman | CFO | Sell | 12,833 | $35.92 | $460,961.36 | 36,265 | |
| 2/15/2018 | Lisa D Earnhardt | Insider | Sell | 15,000 | $36.40 | $546,000.00 | 499,683 | |
| 2/6/2018 | Jeryl L Hilleman | CFO | Sell | 12,833 | $35.80 | $459,421.40 | 25,765 | |
| 2/1/2018 | Richard E Kaufman | COO | Sell | 958 | $37.21 | $35,647.18 | 87,512 | |
| 1/18/2018 | Lisa D Earnhardt | Insider | Sell | 11,166 | $33.47 | $373,726.02 | 495,849 | |
| 1/17/2018 | Richard E Kaufman | COO | Sell | 50,000 | $33.33 | $1,666,500.00 | 107,470 | |
| 1/12/2018 | Gwen R Carscadden | Insider | Sell | 10,000 | $34.35 | $343,500.00 | 13,856 | |
| 1/11/2018 | Jeryl L Hilleman | CFO | Sell | 12,835 | $33.81 | $433,951.35 | 25,767 | |
| 12/15/2017 | Lisa D Earnhardt | Insider | Sell | 10,685 | $31.87 | $340,530.95 | 487,868 | |
| 12/11/2017 | David Aaron Lehman | General Counsel | Sell | 36,000 | $32.75 | $1,179,000.00 | 45,000 | |
| 12/4/2017 | Jeryl L Hilleman | CFO | Sell | 12,833 | $30.06 | $385,759.98 | 27,833 | |
| 11/20/2017 | Frederic H Moll | Director | Sell | 14,200 | $28.76 | $408,392.00 | 247,124 | |
| 11/16/2017 | Frederic H Moll | Director | Sell | 6,700 | $28.77 | $192,759.00 | 247,124 | |
| 11/10/2017 | Frederic H Moll | Director | Sell | 800 | $29.00 | $23,200.00 | 253,824 | |
| 11/6/2017 | Jeryl L Hilleman | CFO | Sell | 12,833 | $27.78 | $356,500.74 | 27,833 | |
| 10/16/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $28.37 | $567,400.00 | | |
| 10/4/2017 | Jeryl L Hilleman | CFO | Sell | 12,833 | $29.96 | $384,476.68 | | |
| 9/25/2017 | Richard E Kaufman | COO | Sell | 13,639 | $28.97 | $395,121.83 | 133,757 | |
| 9/15/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $30.19 | $603,800.00 | 525,868 | |
| 9/5/2017 | Jeryl L Hilleman | CFO | Sell | 12,833 | $31.05 | $398,464.65 | 27,833 | |
| 8/28/2017 | Richard E Kaufman | COO | Sell | 22,425 | $30.22 | $677,683.50 | 149,821 | |
| 8/15/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $30.79 | $615,800.00 | 525,868 | |
| 8/4/2017 | Jeryl L Hilleman | CFO | Sell | 12,833 | $29.00 | $372,157.00 | 27,833 | |
| 7/25/2017 | Richard E Kaufman | COO | Sell | 12,500 | $28.25 | $353,125.00 | 169,821 | |
| 7/17/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $29.03 | $580,600.00 | 580,868 | |
| 7/10/2017 | Jeryl L Hilleman | CFO | Sell | 12,835 | $27.18 | $348,855.30 | 27,835 | |
| 6/15/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $26.10 | $522,000.00 | 583,493 | |
| 5/22/2017 | Richard E Kaufman | COO | Sell | 20,000 | $22.87 | $457,400.00 | 182,321 | |
| 5/15/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $22.98 | $459,600.00 | 600,868 | |
| 4/20/2017 | Richard E Kaufman | COO | Sell | 1,250 | $17.25 | $21,562.50 | 202,321 | |
| 4/17/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $16.06 | $321,200.00 | 610,868 | |
| 3/15/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $15.02 | $300,400.00 | 620,868 | |
| 10/20/2016 | Richard E Kaufman | COO | Sell | 3,603 | $16.58 | $59,737.74 | 194,571 | |
| 10/17/2016 | Lisa D Earnhardt | Insider | Sell | 400 | $18.00 | $7,200.00 | 557,268 | |
| 9/7/2016 | Amy Wolbeck | VP | Sell | 28,664 | $15.83 | $453,751.12 | 18,076 | |
| 9/6/2016 | James Stambaugh | VP | Sell | 4,000 | $16.00 | $64,000.00 | 23,700 | |
| 8/3/2016 | James Stambaugh | VP | Sell | 3,977 | $17.00 | $67,609.00 | 27,977 | |
| 7/18/2016 | James Stambaugh | VP | Sell | 5,000 | $15.33 | $76,650.00 | 29,000 | |
| 6/13/2016 | James Stambaugh | VP | Sell | 500 | $14.38 | $7,190.00 | 24,000 | |
| 5/16/2016 | Kieran Gallahue | Director | Buy | 8,000 | $12.64 | $101,120.00 | 8,000 | |
| 4/27/2016 | Amy Wolbeck | VP | Sell | 2,000 | $20.01 | $40,020.00 | 7,700 | |
| 4/20/2016 | Richard E Kaufman | COO | Sell | 3,603 | $18.86 | $67,952.58 | 198,174 | |
| 4/18/2016 | Lisa D Earnhardt | CEO | Sell | 28,500 | $18.69 | $532,665.00 | 581,368 | |
| 3/21/2016 | Richard E Kaufman | COO | Sell | 3,603 | $16.51 | $59,485.53 | 201,777 | |
| 3/15/2016 | Lisa D Earnhardt | CEO | Sell | 9,000 | $18.01 | $162,090.00 | 561,368 | |
| 3/14/2016 | Frederic H Moll | Director | Sell | 1,299 | $18.53 | $24,070.47 | 252,078 | |
| 3/8/2016 | Frederic H Moll | Director | Sell | 601 | $18.56 | $11,154.56 | 253,377 | |
| 2/22/2016 | Richard E Kaufman | COO | Sell | 3,603 | $18.65 | $67,195.95 | 205,380 | |
| 1/21/2016 | Richard E. Kaufman | COO | Sell | 7,206 | $17.93 | $129,203.58 | 208,983 | |
| 1/15/2016 | Lisa D. Earnhardt | CEO | Sell | 12,500 | $19.26 | $240,750.00 | 570,368 | |
| 12/15/2015 | Lisa D Earnhardt | CEO | Sell | 6,820 | $19.85 | $135,377.00 | 574,868 | |
| 11/16/2015 | Lisa D Earnhardt | CEO | Sell | 6,818 | $18.00 | $122,724.00 | 581,688 | |
| 10/15/2015 | Lisa D Earnhardt | CEO | Sell | 6,818 | $18.72 | $127,632.96 | 588,506 | |
| 9/15/2015 | Lisa D Earnhardt | CEO | Sell | 6,818 | $25.99 | $177,199.82 | 595,324 | |
| 9/11/2015 | Frederic H Moll | Director | Sell | 10,000 | $25.21 | $252,100.00 | 282,428 | |
| 8/17/2015 | Lisa D Earnhardt | CEO | Sell | 6,818 | $28.51 | $194,381.18 | | |
| 7/20/2015 | James Stambaugh | VP | Sell | 12,000 | $30.52 | $366,240.00 | | |
| 7/15/2015 | Lisa D Earnhardt | CEO | Sell | 19,318 | $29.62 | $572,199.16 | | |
| 6/15/2015 | Lisa D Earnhardt | CEO | Sell | 19,318 | $29.30 | $566,017.40 | | |
| 5/8/2015 | James Stambaugh | VP | Sell | 2,785 | $23.87 | $66,477.95 | | |
| 4/13/2015 | Amy Wolbeck | VP | Sell | 16,000 | $26.25 | $420,000.00 | | |
| 4/1/2015 | James Stambaugh | VP | Sell | 8,343 | $25.50 | $212,746.50 | | |
| 3/16/2015 | Lisa D Earnhardt | Insider | Sell | 19,318 | $23.56 | $455,132.08 | | |
| 3/11/2015 | Amy Wolbeck | VP | Sell | 8,000 | $23.06 | $184,480.00 | | |
| 3/9/2015 | James Stambaugh | VP | Sell | 8,343 | $23.02 | $192,055.86 | | |
| 2/17/2015 | Lisa D Earnhardt | Insider | Sell | 19,318 | $22.69 | $438,325.42 | | |
| 2/12/2015 | Amy Wolbeck | VP | Sell | 8,000 | $22.12 | $176,960.00 | | |
| 2/2/2015 | James Stambaugh | VP | Sell | 8,343 | $20.98 | $175,036.14 | | |
| 1/26/2015 | Robert H Binney Jr | VP | Sell | 6,300 | $21.18 | $133,434.00 | | |
| 9/11/2014 | Cynthia L Lucchese | Director | Buy | 5,000 | $17.11 | $85,550.00 | | |
(Data available from 1/1/2013 forward)
Intersect ENT (NASDAQ XENT) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Intersect ENT (XENT) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 20 at 3:40 AM |
| Zacks: Analysts Expect Intersect ENT (XENT) Will Post Quarterly Sales of $28.02 Million
www.americanbankingnews.com - May 20 at 3:06 AM |
 | Notable Friday Option Activity: XENT, LGIH, ACHC
www.nasdaq.com - May 18 at 4:51 PM |
| -$0.17 EPS Expected for Intersect ENT (XENT) This Quarter
www.americanbankingnews.com - May 18 at 1:43 PM |
 | JPMorgan Says CMS Decision on Sinuva is Likely an Error Following Discussion with Management (XENT)
www.streetinsider.com - May 12 at 9:50 AM |
| Jeryl L. Hilleman Sells 12,833 Shares of Intersect ENT (XENT) Stock
www.americanbankingnews.com - May 7 at 7:40 PM |
| Intersect ENT (XENT) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - May 7 at 4:26 PM |
| Q4 2018 EPS Estimates for Intersect ENT (XENT) Increased by William Blair
www.americanbankingnews.com - May 7 at 4:16 AM |
| Intersect ENT (XENT) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - May 5 at 3:13 PM |
| Brokers Set Expectations for Intersect ENT's Q2 2018 Earnings (XENT)
www.americanbankingnews.com - May 4 at 5:50 AM |
| Q2 2018 EPS Estimates for Intersect ENT (XENT) Lifted by Leerink Swann
www.americanbankingnews.com - May 4 at 5:50 AM |
| $28.05 Million in Sales Expected for Intersect ENT (XENT) This Quarter
www.americanbankingnews.com - May 3 at 8:42 AM |
| Intersect ENT's (XENT) Hold Rating Reaffirmed at Northland Securities
www.americanbankingnews.com - May 2 at 4:52 PM |
| Intersect ENT (XENT) Upgraded to "Strong-Buy" by ValuEngine
www.americanbankingnews.com - May 2 at 1:37 PM |
| Intersect ENT (XENT) Receives Hold Rating from BTIG Research
www.americanbankingnews.com - May 2 at 11:28 AM |
 | Intersect ENT's (XENT) CEO Lisa Earnhardt on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 2 at 9:11 AM |
| Intersect ENT beats by $0.03, beats on revenue
seekingalpha.com - May 2 at 9:11 AM |
 | Edited Transcript of XENT earnings conference call or presentation 1-May-18 8:30pm GMT
finance.yahoo.com - May 2 at 9:11 AM |
| Intersect ENT (XENT) Earns "Overweight" Rating from JPMorgan Chase
www.americanbankingnews.com - May 2 at 7:54 AM |
| Intersect ENT (XENT) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 1 at 9:10 PM |
| Intersect ENT Reports First Quarter 2018 Results
finance.yahoo.com - May 1 at 4:34 PM |
| Intersect ENT (XENT) Expected to Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - May 1 at 1:10 AM |
| Intersect ENT (XENT) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 25 at 3:40 AM |
| Intersect ENT (XENT) to Release Earnings on Monday
www.americanbankingnews.com - April 23 at 8:26 AM |
| Intersect ENT (XENT) Receives New Coverage from Analysts at Berenberg Bank
www.americanbankingnews.com - April 20 at 11:55 AM |
| Intersect ENT (XENT) Insider Sells $593,850.00 in Stock
www.americanbankingnews.com - April 17 at 7:13 PM |
| Intersect ENT to Present at Deutsche Bank and Bank of America Merrill Lynch Conferences
finance.yahoo.com - April 17 at 5:05 PM |
| Intersect ENT (XENT) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - April 17 at 9:57 AM |
| Intersect ENT to Report First Quarter 2018 Financial Results
finance.yahoo.com - April 16 at 4:35 PM |
| $23.68 Million in Sales Expected for Intersect ENT (XENT) This Quarter
www.americanbankingnews.com - April 16 at 5:03 AM |
| Intersect ENT (XENT) Given a $31.00 Price Target by Deutsche Bank Analysts
www.americanbankingnews.com - April 14 at 9:37 AM |
| Intersect ENT (XENT) Upgraded by TheStreet to C-
www.americanbankingnews.com - April 13 at 7:51 PM |
| Commit To Buy Intersect ENT At $30, Earn 9.7% Annualized Using Options
www.nasdaq.com - April 13 at 4:40 PM |
| Zacks Investment Research Reiterates "Hold" Rating for Intersect ENT (XENT)
www.americanbankingnews.com - April 7 at 4:27 PM |
| Insider Selling: Intersect ENT Inc (XENT) CFO Sells 12,833 Shares of Stock
www.americanbankingnews.com - April 4 at 10:56 PM |
| Intersect ENT (XENT) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 4 at 12:55 PM |
 | Intersect ENT Announces Launch of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal ...
www.businesswire.com - April 3 at 9:31 AM |
| Intersect ENT (XENT) Lifted to "Buy" at ValuEngine
www.americanbankingnews.com - April 2 at 10:26 PM |
| Intersect ENT Announces Launch of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
finance.yahoo.com - April 2 at 9:43 AM |
| Intersect ENT's (XENT) Hold Rating Reiterated at BTIG Research
www.americanbankingnews.com - April 1 at 4:16 PM |
| Intersect ENT Inc (XENT) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 31 at 3:38 AM |
| $23.68 Million in Sales Expected for Intersect ENT Inc (XENT) This Quarter
www.americanbankingnews.com - March 30 at 4:19 AM |
| Zacks: Brokerages Anticipate Intersect ENT Inc (XENT) Will Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - March 28 at 3:13 AM |
| Reviewing Reshape Lifesciences (RSLS) & Intersect ENT (XENT)
www.americanbankingnews.com - March 25 at 9:04 PM |
| Intersect ENT (XENT) Upgraded to "Buy" by BidaskClub
www.americanbankingnews.com - March 25 at 2:00 PM |
| Intersect ENT (XENT) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - March 24 at 11:46 PM |
| Intersect ENT (XENT) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - March 22 at 9:21 AM |
| Intersect ENT Inc (XENT) Insider Lisa D. Earnhardt Sells 15,000 Shares
www.americanbankingnews.com - March 16 at 7:34 PM |
| Zacks: Brokerages Expect Intersect ENT Inc (XENT) Will Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - March 10 at 7:14 PM |
| Intersect ENT Inc (XENT) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 6 at 3:28 AM |
Intersect ENT (NASDAQ:XENT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Intersect ENT (NASDAQ:XENT) Income Statement, Balance Sheet and Cash Flow Statement
Intersect ENT (NASDAQ XENT) Stock Chart for Friday, May, 25, 2018
Loading chart…
